Abstract
Purpose :
To utilize optical bench measurements and available clinical data from commercially available IOLs (PanOptix, TFNT00; Alcon) to predict the clinical performance of a novel trifocal IOL (enVista Trifocal, EN; Bausch and Lomb).
Methods :
Modeling of visual acuity is based on a combination of optical bench data and clinical data of commercially available IOLs. Optical characteristics (MTF) of the IOLs are measured using Optispheric Pro (Trioptics, Germany). The measurements and modeling presented here used model 1 cornea with +0.27 microns of spherical aberration. MTF values were measured using 3 mm (photopic) and 4.5 mm (mesopic) apertures. Clinical data were derived from multifocal diffractive IOLs from published literature. These clinically projected results are high contrast visual acuity in photopic and mesopic conditions.
Results :
MTF values at 50 lp/mm and 3.0 mm (photopic) were equivalent at distance between EN and TFNT00. EN showed slightly better MTF values at intermediate and near. At 4.5 mm (mesopic) at distance, EN measured higher at 0.45 compared to 0.39 for TFNT00, for intermediate and near, TFNT00 was slightly better than EN(Table 1). Clinical outcomes based on predictive modeling for EN are expected to be non-inferior to monofocal for distance, at least 20/32 for near and intermediate under photopic conditions, and 20/40 or better for near and intermediate under mesopic conditions (Table 2).
Conclusions :
Optical bench measurements showed enVista Trifocal to be equivalent to TFNT00 at distance and slightly better at near and intermediate under photopic conditions. The new trifocal appeared to be more distance-dominated under mesopic conditions with higher MTF values at distance and lower near and intermediate values when compared to models like TFNT00. Clinical modeling for enVista Trifocal were predicted to be non-inferior to monofocals at distance and 20/40 or better for near and intermediate under mesopic and photopic conditions.
This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.